Background
==========

Prostate cancer (PCa) is one of the most frequently occurring cancers and cause of cancer-related deaths in men \[[@B1]\]. According to the latest report from the American Cancer Society, in 2014, 233,000 new cases will be diagnosed, and 29,480 estimated deaths from PCa are predicted in the United States \[[@B1]\]. Although the five-year relative survival rate has increased over the past 25 years \[[@B2]\], PCa is still the leading cause of cancer death in older men \[[@B1]\]. There is an urgent need for a better understanding of the factors related to PCa development and prognosis.

Cyclooxygenase-2 (COX-2), an inducible enzyme, is overexpressed in PCa tissue \[[@B3]\] and plays a role in PCa cell growth \[[@B4]\]. Aberrant or high expression of COX-2 has been implicated in carcinogenesis and poorer prognosis \[[@B5],[@B6]\]. Therefore, it has been speculated that non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit the COX pathway, may provide a strategy for mechanistically based PCa chemoprevention and therapy \[[@B3]\]. Indeed, a number of epidemiologic studies have investigated the association between NSAID use and the risk of PCa but showed conflicting results, with the majority finding null effects \[[@B7]-[@B22]\], some reporting statistically significant inverse associations \[[@B23]-[@B34]\] and a minority reporting a significantly elevated risk of prostate cancer in association with NSAID or non-aspirin NSAID (NA-NSAID) use \[[@B35]-[@B37]\]. In a study conducted by Mahmud *et al*. \[[@B38]\], which searched databases in June 2008, the association of the use of aspirin and other NSAIDs with PCa incidence was suggestive but not conclusive. Several observational studies published after this meta-analysis have shown contrasting results \[[@B19]-[@B22],[@B32]-[@B34],[@B36],[@B37]\], which has added new evidence to the previous research. On the other hand, since considerable evidence implies that aspirin use may reduce the risk of PCa, a better understanding of whether such therapy can influence disease outcome is important and necessary. To date, several studies have examined NSAID (aspirin) use and PCa-specific mortality, and these have reported conflicting findings \[[@B39]-[@B46]\].

Given widespread and long-term NSAID use, more knowledge is needed to clarify the drugs' role in PCa incidence and mortality. Therefore, we performed a comprehensive review and provide a quantitative assessment of all relevant published studies to understand this issue better. A better understanding of the relationship may also highlight the importance of considering additional prevention methods in this area.

Methods
=======

Data sources and searches
-------------------------

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist \[see Additional file [1](#S1){ref-type="supplementary-material"}\] \[[@B47]\]. Three authors (YL, JC and LX) experienced in Cochrane review searched electronic databases for articles published through 29 December 2013. The databases included PubMed, Embase, ISI Web of Science and the WHO Library Database. The search terms included the therapeutic classes, generic names of individual drugs and PCa outcome terms \[see Additional file [2](#S2){ref-type="supplementary-material"}\]. No language restrictions were imposed. Additional studies were searched for manually through the reference lists of retrieved articles and using PubMed's related articles option.

Eligibility criteria and study selection
----------------------------------------

To be included, studies had to meet the following criteria: (1) studied participants were exposed to any NSAID, including aspirin, NA-NSAIDs, any other single NSAID (not including acetaminophen) or a mixture of NSAIDs or selective COX-2 inhibitors and reference participants had not used these drugs; (2) the study assessed the incidence of PCa or PCa-specific mortality; and (3) the study reported the multivariate-adjusted relative risks (RRs), including study-specific odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (CIs). No study design restrictions were imposed. Reviews, letters, comments, lectures and case reports were all excluded. When study populations overlapped, only the study of larger size or the most informative one was included. However, if overlapping studies offered additional information for subgroup analysis that could not be extracted from the primary studies, they were included in the subgroup analysis. Two authors (JW, TL) independently evaluated all records by title and abstract and subsequently retrieved and assessed in detail the full text of any potentially relevant articles according to the eligibility criteria. Disagreements or uncertainties regarding eligibility were resolved through discussion with two additional adjudicators (XQ, SL).

Data extraction and quality assessment
--------------------------------------

For each trial, the study and participant characteristics, number of cases and controls, drug types, exposure period and multivariable adjusted RR estimates with corresponding 95% CIs were extracted and transferred to specially designed forms. If the required data for the meta-analysis were not readily available in the published article, the principal author was contacted at least once. Data were obtained and independently reviewed by two reviewers (YL and SL), and the final decision was reached by consensus. The methodological quality of observational studies was assessed by two authors (XQ and YL) independently using the Newcastle-Ottawa scale (NOS) \[[@B48]\]. Disagreement was resolved by consensus. In this scale, studies are awarded a maximum score of 9 points; a high-quality study is awarded ≥7 points, a medium-quality study between 4 and 6 points and a poor-quality study \<4 points.

Data synthesis and statistical analysis
---------------------------------------

We evaluated the association of NSAID use with two endpoints: (1) the OR of PCa incidence and (2) the HRs of PCa-specific mortality. Pooled ORs and HRs with 95% CI were obtained using a fixed effects model \[[@B49]\] or the random effects model of DerSimonian and Laird \[[@B50]\] if needed due to between-study heterogeneity. Because the evaluated outcomes are relatively rare and the effects estimated are generally small, ORs in case--control studies were considered reasonable approximations of the corresponding risk ratios in cohort studies \[[@B51]\], permitting the combination of cohort and case--control studies. Inter-study heterogeneity was tested by Cochran's Q test \[[@B52]\] and quantified by the *I*^*2*^ statistics \[[@B53]\]. For the Q statistic, a *P* value \<0.10 was considered statistically significant for heterogeneity; for *I*^*2*^, a value \>50% indicates a measure of heterogeneity \[[@B52]\]. Cumulative meta-analysis was conducted to examine how the evidence has changed over time. We assessed publication bias graphically using a funnel plot and quantitatively using the Begg rank correlation test and the Egger regression asymmetry test \[[@B54],[@B55]\] where numbers of studies allowed (\>10 studies). Sensitivity analyses were also conducted to assess the robustness of the results by the sequential omission of individual studies \[[@B56]\].

To detect potential interactions, studies were stratified by the type of medicine (NSAIDs overall, aspirin, NA-NSAIDs and COX-2 inhibitors) and study outcome (total PCa (all cancers regardless of stage), advanced cancers (lesions with extracapsular extension or metastases to regional lymph nodes or other organs) and non-advanced cancers). Further subgroup analysis estimated the effects of NSAIDs on PCa risk by study design, studies defined as high quality, geographic region and duration of aspirin use. A two-tailed *P* value \<0.05 was considered statistically significant. All analyses were performed using STATA version 12.0 (StataCorp, College Station, TX, USA).

Results
=======

Study selection, characteristics and quality
--------------------------------------------

Our initial search identified 4,331 studies, of which we obtained 51 full-text articles, and 39 studies \[[@B7]-[@B37],[@B39]-[@B46]\] were included in the review. References for studies excluded from the full-text study review process and the additional records identified through a manual review are listed in Additional file [3](#S3){ref-type="supplementary-material"}. A PRISMA trial flow diagram for systematic review is presented in Figure [1](#F1){ref-type="fig"}. One article from the Cancer Prevention Study II Nutrition Cohort by Jacobs *et al*. \[[@B18]\] in 2007 was excluded from the primary outcome analysis because this article only updated the duration-effect of aspirin contrasting the primary group \[[@B14]\]; therefore, the study data were re-entered for subgroup analyses for duration of aspirin.

![Flow of selection for studies through review.](1741-7015-12-55-1){#F1}

The studies that met the inclusion criteria were all observational studies, comprising 20 case--control \[[@B9]-[@B11],[@B16],[@B17],[@B21]-[@B23],[@B26],[@B28]-[@B33],[@B35]-[@B37],[@B41]\],\[[@B44]\] and 19 cohort studies \[[@B7],[@B8],[@B12]-[@B15],[@B18]-[@B20],[@B24],[@B25],[@B27],[@B34]\],\[[@B39],[@B40],[@B42],[@B43],[@B45],[@B46]\] involving more than 924,502 male subjects, including 108,136 PCa cases. Thirty-one studies (18 case--control \[[@B9]-[@B11],[@B16],[@B17],[@B21]-[@B23],[@B26],[@B28]-[@B33],[@B35]-[@B37]\] and 13 cohort \[[@B7],[@B8],[@B12]-[@B15],[@B18]-[@B20],[@B24],[@B25],[@B27],[@B34]\]) addressed the use of any NSAID and its association with PCa incidence risk (Table [1](#T1){ref-type="table"}); eight studies (two case--control \[[@B41],[@B44]\] and six cohort \[[@B39],[@B40],[@B42],[@B43],[@B45],[@B46]\]) investigated whether NSAID use was associated with PCa-specific mortality (Table [2](#T2){ref-type="table"}). For NSAID use and PCa incidence risk, the publication dates of the studies ranged between 1989 and 2014. A majority of the studies were conducted in North America (16 in the USA and four in Canada) and 10 in Europe. For NSAID use and PCa-specific mortality, five studies \[[@B39]-[@B41],[@B43],[@B45]\] measured exposure to aspirin, one study \[[@B44]\] addressed any NSAIDs, one study \[[@B46]\] covered only NA-NSAIDs, and one study \[[@B42]\] employed all three categories.

###### 

Characteristics of included studies: any NSAIDs use and PCa incidence risk

              **Study**              **Study location**   **Cases (number)**     **Controls (number)**     **Age (y)**^**a**^     **Exposure period**                 **Drugs studied**               **Outcome (number)**        **Information source**             **Confounders for adjustment**       **Quality score**
  --------------------------------- -------------------- -------------------- --------------------------- -------------------- -------------------------- ------------------------------------------ ---------------------- ----------------------------------- ---------------------------------------- -------------------
      **Case--control studies**                                                                                                                                                                                                                                                                                    
     Veitonmaki, 2013 \[[@B37]\]          Finland               24,657                  24,657                     68                  1995--2002          ASA/NSAIDs/ NA-NSAIDs/ COX-2 inhibitors     Total/advanced PCa                Database                                 1--5                            8
        Kopp, 2013 \[[@B22]\]             Denmark                334                      334                     59.0                 1993--1997                           NSAIDs                         Total PCa                   Questionnaire                            1, 6, 7                           4
    Vinogradova, 2011 \[[@B21]\]             UK                 14,764                  192,081                    69                  1997--2008                      COX-2 inhibitors                    Total PCa                     Database                               1, 8--11                          7
       Murad, 2011 \[[@B36]\]                UK                 1,016                    5,043                     63                  2001--2008                   ASA/NSAIDs/ NA-NSAIDs                  Total PCa                   Questionnaire                           1, 12--15                          6
       Mahmud, 2011 \[[@B33]\]             Canada               9,007                   36,028                     73                  1985--2000                   ASA/NSAIDs/ NA-NSAIDs                  Total PCa                     Database                              1, 14--17                          6
      Salinas, 2010 \[[@B32]\]              USA                 1,001                     942                      63                  2002--2005              ASA/ NA-NSAIDs/ COX-2 inhibitors        Total/advanced PCa              Questionnaire                           1, 17--18                          7
       Harris, 2007 \[[@B31]\]              USA                  229                      285                      NR                  2002--2004              ASA/ NA-NSAIDs/ COX-2 inhibitors            Total PCa                     Interview                            1, 6, 19--21                        5
      Menezes, 2006 \[[@B17]\]              USA                 1,029                    1,029                     67                  1982--1998                            ASA                       Total/advanced PCa              Questionnaire                            1, 6, 12                          4
       Mahmud, 2006 \[[@B30]\]             Canada                494                      805                      64                  1999--2003          ASA/ NSAIDs/ NA-NSAIDs/ COX-2 inhibitors    Total/advanced PCa              Questionnaire                     1, 12, 14, 15, 22--25                    6
        Liu, 2006 \[[@B29]\]                USA                  506                      506                      NR                  2001--2004                  ASA/ NSAIDs / NA-NSAIDs                Advanced PCa                   Interview                             1, 18, 26                          5
      Dasgupta, 2006 \[[@B28]\]            Canada               2,025                    2,150                     73                  1999--2002                       ASA/ NA-NSAIDs                     Total PCa                     Database                                1, 27                            6
      Bosetti, 2006 \[[@B16]\]             Italy                1,261                    1,131                     65                  1991--2002                            ASA                       Total/advanced PCa              Questionnaire                          1, 7, 12, 28                        5
       Perron, 2003 \[[@B26]\]             Canada               2,221                   11,105                    75.7                 1993--1995                       ASA/ NA-NSAIDs                     Total PCa                     Database                                1, 29                            6
       Irani, 2002 \[[@B11]\]              France                639                      659                     66.8                 1999--2000                       ASA/ NA-NSAIDs                     Total PCa                   Questionnaire                   1, 14, 15, 18, 27, 30--32                  6
       Nelson, 2000 \[[@B23]\]              USA                  417                      420                     64.0                 1992--1995                     NA-NSAIDs/ NSAIDs                    Total PCa                     Interview                             1, 18, 23                          6
      Langman, 2000 \[[@B35]\]               UK                 1,813                    5,354                     NR                  1993--1995                           NSAIDs                         Total PCa                     Database                                 1, 9                            6
      Norrish, 1998 \[[@B10]\]          New Zealand              317                      480                     70.0                    1996                      ASA/ NSAIDs/ NA-NSAIDs             Total/advanced PCa              Questionnaire                           1, 33--36                          7
       Neugut, 1998 \[[@B9]\]               USA                  319                      189                     69.0                 1984--1986                            ASA                           Total PCa                   Medical notes                         1, 18, 13, 22                        6
         **Cohort studies**                                                    **All subjects (number)**                        **Median follow-up (y)**                                                                                                                                                           
       Shebl, 2012 \[[@B34]\]               USA                 3,573                   29,450                    62.8                    11.7                          ASA/NA-NSAIDs                  Total/advanced PCa              Questionnaire                   1, 12, 14, 15, 17, 18, 28                  6
      Dhillon, 2011 \[[@B20]\]              USA                 4,858                   51,529                    64.8                    18.0                               ASA                       Total/advanced PCa              Questionnaire               1, 4, 6, 9, 12, 18, 20, 31, 36--39             8
       Brasky, 2010 \[[@B19]\]              USA                 1,550                   34,132                   50--76                    NR                           ASA/ NA-NSAIDs                 Total/advanced PCa       Questionnaire and Database          1, 6, 7, 12, 13, 18, 22, 39--45               5
       Jacobs, 2007 \[[@B18]\]              USA                 1,076                   69,810                     NR             104,854 person-years                       ASA                           Total PCa         Questionnaire and medical records   1, 6, 7, 9, 13, 15, 18, 20, 22, 45--47           7
       Platz, 2005 \[[@B15]\]               USA                  141                     1,244                    70.0                    9.0                       ASA/NSAIDs/ NA-NSAIDs                  Total PCa                   Questionnaire                       1, 14, 15, 23, 37,                     7
       Jacobs, 2005 \[[@B14]\]              USA                 4,853                   70,144                     NR                  1992--2001                   ASA/NSAIDs/ NA-NSAIDs              Total/advanced PCa              Questionnaire                   1, 7, 12, 13, 18, 22, 45,                  7
    G-Rodriguez, 2004 \[[@B27]\]             UK                 2,183                   12,183                   50--79                1995--2001                       ASA/NA-NSAIDs                  Total/advanced PCa                Database                        1, 14, 15, 17, 37, 48                    8
      Sorensen, 2003 \[[@B13]\]           Denmark                324                    172,057                    NR                     5.4                             NA-NSAIDs                        Total PCa                     Database                              1, 10, 11                          7
       Friis, 2003 \[[@B12]\]             Denmark                196                    29,470                    70.0                    4.1                                ASA                           Total PCa                     Database                              1, 10, 11                          7
      Roberts, 2002 \[[@B25]\]              USA                   91                     1,362                    64.0                    5.5                               NSAIDs                         Total PCa                   Questionnaire                         1, 10, 12, 20                        7
       Habel, 2002 \[[@B24]\]               USA                 2,574                   90,100                   18--84                   14.0                               ASA                       Total/advanced PCa              Questionnaire                         1, 7, 17, 18,                        6
   Schreinemachers, 1994 \[[@B8]\]          USA                  123                    12,668                    65.0                    12.4                               ASA                           Total PCa                     Interview                          1, 7, 9, 18, 21                       5
    Paganini-Hill, 1989 \[[@B7]\]           USA                  149                     5106                      73                     6.5                                ASA                           Total PCa                   Questionnaire                               1                              3

^a^average, median or range.Confounders for adjustment: 1, age; 2, benign prostatic hyperplasia medication use; 3, anti-diabetic medication; 4, cholesterol-lowering medication use; 5, antihypertensive medication use; 6, body mass index; 7, school education; 8, deprivation; 9, smoking; 10, comorbidities; 11, use of medication; 12, family history of prostate cancer; 13, diabetes status; 14, aspirin use; 15, any NA-NSAID use; 16, ever visited a urologist 1 to 11 years prior; 17, screened and volume of family physician visits; 18, race; 19, family history; 20, physical activity; 21, alcohol intake; 22, history of heart disease; 23, intake of acetaminophen; 24, reasons for referral and prostate volume; 25, selective cyclooxygenase-2 (COX-2) inhibitors use; 26, medical institution; 27, finasteride use; 28, study center; 29, recent medical contacts; 30, farming; 31, frequency of red meat and red wine consumption; 32, urological center; 33, socio-economic status; 34, total polyunsaturated fat consumption; 35, α-linolenic acid; 36, fatty acids; 37, period; 38, height; 39, vitamin; 40, osteoarthritis; 41, rheumatoid arthritis; 42, chronic joint pain; 43, chronic headaches; 44, migraines; 45, PSA test in the past two years; 46, history of colorectal endoscopy; 47, hypertension; 48, prior benign prostate hyperplasia history. ASA, aspirin; COX-2, cyclooxygenase enzymes-2; NA-NSAIDs, non-aspirin NSAIDs; NR, not reported; PCa, prostate cancer; y, years.

###### 

Characteristics of included studies: any NSAIDs use and prostate cancer-specific mortality

  **Study**                      **Study location**   **Study design**        **PCa Cases (number)**   **Died from PCa (number)**   **Age (y)**   **Median follow-up (y)**       **Drugs studied**        **Treatment**     **Tumor stage**   **Confounders for adjustment**   **Quality score**
  ------------------------------ -------------------- ---------------------- ------------------------ ---------------------------- ------------- -------------------------- --------------------------- ------------------ ----------------- -------------------------------- -------------------
  Flahavan, 2014 \[[@B39]\]      Ireland              Cohort                          2,936                       104                  70.5                 5.5                       Aspirin              PR, RT, ADT          I--III                     1--8                        8
  Grytli, 2014 \[[@B40]\]        Norway               Cohort                          3,561                      1,010                 76.3                 3.3                       Aspirin                  ADT               I--IV                 1, 2, 9--13                     7
  Cardwell, 2013 \[[@B41]\]      UK                   Nested case--control            6,339                      1,184                  NR                  6.0                       Aspirin            PR, RT, ADT, EST        I--IV               1, 4, 8, 13--17                   7
  Dhillon, 2012 \[[@B42]\]       USA                  Cohort                          3,986                       265                  68.6                 8.4              Aspirin/NSAIDs/ NA-NSAIDs     PR, RT, EST         I--IIIab           1, 2, 4, 6, 10, 18--29               7
  Choe, 2012 \[[@B43]\]          USA                  Cohort                          5,955                       193                  64.0                 5.8                       Aspirin                 RP, RT             I--IV             1, 2, 9, 10, 29--31                 8
  Stock, 2008 \[[@B44]\]         Canada               Case--control                   1,619                       453                  67.2                  NR                       NSAIDs                  RP, RT             I--IV                 1, 2, 9, 21                     7
  Ratnasinghe, 2004 \[[@B45]\]   USA                  Cohort                            NR                        121                 25--74                 NR                       Aspirin                   NR                NR               1, 4, 19, 21, 32--33                6
  Lipworth, 2004 \[[@B46]\]      Denmark              Cohort                            NR                        296                  48.4                 4.3                      NA-NSAIDs                  NR                NR                      1, 33                        5

Confounders for adjustment: 1, age; 2, tumor grade; 3, tumor size; 4, smoking status; 5, co-morbidity score; 6, year of incidence; 7, pre-diagnostic statin exposure 8, receipt of radiation; 9, prostate-specific antigen level; 10, Gleason score; 11, presence and type of metastases; 12, performance status; 13, androgen deprivation therapy initiated within six months after diagnosis; 14, year of cancer diagnosis; 15, chemotherapy within six months of diagnosis; 16, estrogen therapy during exposure period; 17, comorbidities; 18, family history; 19, race; 20, height; 21, body mass index; 22, vigorous physical activity; 23, vitamin D; 24, fish; 25, red meat; 26, cholesterol-lowering drugs; 27, total kcal; 28, aspirin use before diagnosis; 29, initial treatment; 30, aspirin use; 31, non-aspirin anticoagulant use; 32, poverty index; 33, education; 33, number of prescriptions. ADT, androgen-deprivation therapy; EST, estrogen therapy; NA-NSAIDs, non-aspirin NSAIDs; NR: not reported; RP, radical prostatectomy; RT, radiation therapy; y, years.

With regard to the quality of all the included studies assessed by NOS (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}), 18 studies (46.2%) were graded as having good quality (seven or more points), 20 (51.3%) were graded as medium-quality (four to six points), and one study (2.5%) conducted in 1989 was graded as poor-quality (three points). The details of the quality assessment are presented in Additional file [4](#S4){ref-type="supplementary-material"}.

Association between the use of any NSAID and the incidence of prostate cancer
-----------------------------------------------------------------------------

Eleven studies (eight case-controls and three cohorts) evaluated exposure to any NSAIDs and the incidence of total PCa, and five studies examined the effect of any NSAIDs on the incidence of advanced PCa, but no studies examined non-advanced PCa. Figure [2](#F2){ref-type="fig"} shows the study-specific and pooled ORs and 95% CIs of PCa for any NSAID users versus non-NSAID users. The summary OR for the 11 studies that assessed the effect of any NSAIDs on total PCa was 0.90 (95% CI: 0.75 to 1.07; *I*^*2*^ = 93.5%). The effect estimates were similar for five studies on any NSAIDs and advanced PCa (OR = 0.86, 95% CI: 0.52 to 1.40) (Figure [2](#F2){ref-type="fig"}, Table [3](#T3){ref-type="table"}). These analyses yielded substantial heterogeneity (*I*^*2*^ = 93.5% and *I*^*2*^ = 94.2%, respectively) and revealed that any NSAIDs were not associated with a significant decrease in the incidence of PCa.

![Association between use of any NSAIDs and incidence of prostate cancer.](1741-7015-12-55-2){#F2}

###### 

Results of subgroup analyses by outcome type and NSAIDs type

  **Study characteristics**                         **Number of studies**    **OR (95% CI)**    ***P***~***OR***~**value**   **Effect model**   **Heterogeneity**  
  ------------------------------------------------ ----------------------- ------------------- ---------------------------- ------------------ ------------------- ---------
  **Risk of prostate cancer incidence**                                                                                                                                 
  **Any NSAIDs**                                                                                                                                                        
  **Studies of total prostate cancer**                       11             0.90 (0.75, 1.07)              0.25                   Random              93.5          \<0.001
  Case--control studies                                       8             0.97 (0.79, 1.20)              0.78                   Random              93.8          \<0.001
  Cohort studies                                              3             0.71 (0.47, 1.07)              0.10                   Random              81.4           0.005
  Studies in North America                                    6             0.73 (0.60, 0.88)           **0.001**                 Random              79.6          \<0.001
  Studies in Europe                                           5             1.29 (1.25, 1.34)          **\<0.001**                Fixed               37.2           0.17
  **Studies of advanced prostate cancer**                     5             0.86 (0.52, 1.40)              0.54                   Random              94.2          \<0.001
  **Aspirin**                                                                                                                                                           
  **Studies of total prostate cancer**                       23             0.92 (0.87, 0.97)           **0.002**                 Random              66.2          \<0.001
  Case--control studies                                      13             0.92 (0.85, 0.99)           **0.040**                 Random              63.7           0.001
  Cohort studies                                             10             0.91 (0.83, 0.99)           **0.040**                 Random              71.7          \<0.001
  Studies from North America                                 16             0.92 (0.86, 0.97)           **0.003**                 Random              53.7           0.006
  Studies from Europe                                         7             0.94 (0.82, 1.08)              0.40                   Random              80.7          \<0.001
  High quality studies                                        8             0.89 (0.81, 0.98)           **0.022**                 Random              77.2          \<0.001
  Long-term aspirin use (≥4 years)                            8             0.88 (0.79, 0.99)           **0.038**                 Random              66.8           0.004
  **Studies of advanced prostate cancer**                    13             0.81 (0.73, 0.89)          **\<0.001**                Fixed               23.9           0.20
  Case--control studies                                       7             0.84 (0.73, 0.98)           **0.025**                 Fixed               23.7           0.18
  Cohort studies                                              6             0.77 (0.67, 0.89)          **\<0.001**                Fixed               23.5           0.26
  Studies from North America                                  9             0.82 (0.75, 0.89)          **\<0.001**                Fixed               14.0           0.32
  Studies from Europe                                         4             0.88 (0.75, 1.03)              1.22                   Fixed               48.2           0.12
  High quality studies                                        6             0.81 (0.72, 0.92)           **0.002**                 Fixed               38.1           0.152
  **Studies of non-advanced prostate cancer**                 6             0.96 (0.87, 1.07)             0.460                   Fixed               33.6           0.177
  **Non-aspirin NSAIDs**                                                                                                                                                
  **Studies of total prostate cancer**                       17             1.01 (0.90, 1.13)              0.86                   Random              90.1          \<0.001
  Case--control studies                                      11             0.97 (0.81, 1.17)              0.74                   Random              93.0          \<0.001
  Cohort studies                                              6             1.07 (0.95, 1.20)              0.25                   Random              69.6           0.006
  Studies from North America                                 11             0.94 (0.85, 1.05)              0.28                   Random              68.8          \<0.001
  Studies from Europe                                         6             1.18 (1.06, 1.32)           **0.002**                 Random              71.1           0.004
  **Studies of advanced prostate cancer**                     9             0.99 (0.77, 1.28)              0.97                   Random              81.6          \<0.001
  **Studies of non-advanced prostate cancer**                 3             1.00 (0.90, 1.12)             0.943                   Fixed                0.0           0.897
  **Any COX2 inhibitors**                                                                                                                                               
  **Studies of total prostate cancer**                        5             1.10 (0.90, 1.33)              0.36                   Random              48.7           0.099
  **Studies of advanced prostate cancer**                     3             1.20 (0.79, 1.83)              0.40                   Fixed                0.0           0.87
  **Risk of prostate cancer-specific mortality**                                                                                                                        
  **Any NSAIDs (including aspirin use alone)**                                                                                                                          
  **Studies of total prostate cancer**                        8             1.00 (0.68, 1.47)              0.99                   Random              95.3          \<0.001
  **Aspirin**                                                                                                                                                           
  **Studies of total prostate cancer**                        6             0.86 (0.78, 0.96)           **0.005**                 Fixed               39.2           0.15
  Studies from North America                                  3             0.85 (0.50, 144)               0.55                   Random              63.8           0.063
  Studies from Europe                                         3             0.85 (0.76, 0.95)           **0.005**                 Fixed               12.8           0.32

CI, confidence interval; COX-2, cyclooxygenase enzymes-2; OR, odds ratio.

In sensitivity analyses, none of the individual studies substantially altered the pooled ORs for any NSAIDs on total PCa, which varied from 0.86 (95% CI, 0.71 to 1.04) to 0.96 (95% CI, 0.81 to 1.14). The direction and magnitude of the negative effect did not vary markedly when stratified by study design (Table [3](#T3){ref-type="table"}). However, when we combined studies by geographic region, the six studies from North America had a summary OR of 0.73 (95% CI: 0.60 to 0.88; *P*~*OR*~ =0.001; *I*^*2*^ = 79.6%), whereas the other five studies from Europe had a higher and statistically significant summary OR of 1.29 (95% CI: 1.25 to 1.34; *P*~*OR*~ \<0.001; *I*^*2*^ = 37.2%) (Table [3](#T3){ref-type="table"}).

For publication bias assessment, the inverted funnel plot was potentially asymmetric, and the results of the Begg test (*P* = 0.350) and the Egger test (*P* = 0.037) implied some evidence of publication bias (Figure [3](#F3){ref-type="fig"}A).

![**Funnel plots of the relative risk of total prostate cancer incidence. (A)** for any NSAIDs use; **(B)** for aspirin use; **(C)** for non-aspirin NSAID use.](1741-7015-12-55-3){#F3}

Association between aspirin use and PCa incidence
-------------------------------------------------

Twenty-three studies, thirteen studies, and six studies evaluated exposure to aspirin and the incidence of total PCa, advanced PCa, and non-advanced PCa, respectively. Figure [4](#F4){ref-type="fig"} graphs the ORs and 95% CIs from the individual studies and the pooled results. The 23 studies that assessed the effect of aspirin on total PCa showed an inverse association (OR = 0.92, 95% CI: 0.87 to 0.97) and were moderately heterogeneous (*I*^*2*^ = 66.2%, *P*\<0.001). The 13 studies of advanced PCa were consistent; the risk decrease persisted and was slightly lower than for the total PCa (OR = 0.81, 95% CI: 0.73 to 0.89; *I*^*2*^ = 23.9%). However, a non-significant decreased risk was observed in non-advanced PCa (OR = 0.96, 95% CI: 0.87 to 1.07), with little evidence of heterogeneity (*I*^*2*^ = 34.6%, *P* = 0.177).

![Association between aspirin use and incidence of prostate cancer.](1741-7015-12-55-4){#F4}

We saw no evidence of obvious influential studies in sensitivity analyses by the sequential omission of individual studies. The summary ORs for total cancer were reasonably stable, ranging from 0.91 when the study by Friis *et al*. \[[@B12]\] was excluded to 0.94 when the study by Rodriguez *et al*. \[[@B27]\] was excluded. Table [3](#T3){ref-type="table"} shows the results of the subgroup analyses. The risk decrease persisted for both total and advanced PCa when the data were stratified into subgroups based on study design and study quality. The effect sizes showed moderate statistical heterogeneity among studies of total PCa but no heterogeneity among studies of advanced PCa. Adjustment for geographic region had the strongest influence on the summary OR, demonstrating negative results.

We examined the association between long-term aspirin use (defined as ever use of aspirin for more than four years) and risk of total PCa incidence using the data available from the included studies. Eight studies \[[@B15],[@B17]-[@B20],[@B26],[@B27],[@B32]\] were included in this analysis. The pooled results slightly strengthened the association of aspirin use with total PCa (OR: 0.88, 95% CI: 0.79, 0.99) (see Table [3](#T3){ref-type="table"} and Additional file [5](#S5){ref-type="supplementary-material"}: Figure S1). Most studies lacked information on the dose and frequency of aspirin use, or the information varied in each trial; hence, a statistical analysis of significance between these groups was not valid.

A visual inspection of the funnel plot found no evidence of publication bias (Figure [3](#F3){ref-type="fig"}B). The *P* values for the Begg test and the Egger test were *P* = 0.316 and *P* = 0.273, respectively, both suggesting a very low probability of publication bias.

A cumulative meta-analysis of a total of 23 studies of total PCa was carried out to evaluate the cumulative effect estimate over time. In 1989, Paganini-Hill *et al*. \[[@B7]\] first reported a non-significant effect estimate of 0.95. Between 1994 and 2006, 14 studies were published, with a cumulative OR of 0.89 (95% CI: 0.81 to 0.98). A statistically significant effect of aspirin use on PCa incidence was consistently observed after publication of the 13th trial in 2006. Between 2007 and 2013, eight more publications were added cumulatively, resulting in an overall effect estimate of 0.92 (95% CI 0.87 to 0.97) \[see Additional file [5](#S5){ref-type="supplementary-material"}: Figure S2\].

Association between NA-NSAID use and PCa incidence
--------------------------------------------------

Seventeen studies, nine studies, and three studies evaluated exposure to NA-NSAID and the incidence of total PCa, advanced PCa, and non-advanced PCa, respectively. Figure [5](#F5){ref-type="fig"} illustrates the ORs and 95% CIs from the individual studies and the pooled results. The meta-analysis revealed that NA-NSAID use was not significantly associated with the incidence of PCa (OR = 1.01, 95% CI: 0.90 to 1.13 for total cancer; OR = 0.99, 95% CI: 0.77 to 1.28 for advanced cancer; OR = 1.00, 95% CI: (0.90 to 1.12 for non-advanced cancer), both with substantial heterogeneity between studies except for non-advanced PCa analysis. Table [2](#T2){ref-type="table"} presents the results of subgroup analyses.

![Association between non-aspirin NSAID use and incidence of prostate cancer.](1741-7015-12-55-5){#F5}

For publication bias, the funnel plot was slightly asymmetric (Figure [3](#F3){ref-type="fig"}C), and the *P* values for the Begg test and the Egger test were 0.711 and 0.050, respectively, suggesting a low probability of publication bias.

Association between any COX-2 inhibitor use and PCa incidence
-------------------------------------------------------------

Five studies \[[@B21],[@B30]-[@B32],[@B37]\] evaluated COX-2 inhibitor use and PCa risk. Overall, use of COX-2 inhibitors appeared not to be statistically significantly associated with PCa risk compared to non-use (Table [3](#T3){ref-type="table"}; Additional file [5](#S5){ref-type="supplementary-material"}: Figure S3). For studies with small numbers, we did not perform subgroup analyses.

Association between any NSAID use and PCa-specific mortality
------------------------------------------------------------

Eight studies \[[@B39]-[@B46]\] investigated exposure to any NSAIDs use (including aspirin use alone) with PCa-specific mortality (Table [2](#T2){ref-type="table"}). The pooled result shows that the use of any NSAID had a neutral influence on the PCa-specific mortality in a random effects model, with an HR = 1.00 (95% CI: 0.68, 1.47) but with substantial heterogeneity (*I*^*2*^ = 95.3%) (Table [3](#T3){ref-type="table"} and Additional file [5](#S5){ref-type="supplementary-material"}: Figure S4). Studies of aspirin were more consistent; the pooled results indicated that aspirin use was statistically significantly associated with a modest reduction in PCa-specific mortality (OR = 0.86, 95% CI: 0.78 to 0.96), with little evidence of heterogeneity (Table [3](#T3){ref-type="table"} and Figure [6](#F6){ref-type="fig"}). Confined to three studies from North America, the HR was 0.85 (95% CI: 0.50 to 144) but with more substantial heterogeneity (*I*^*2*^ = 6%).

![Association between aspirin use and prostate cancer-specific mortality.](1741-7015-12-55-6){#F6}

Discussion
==========

This meta-analysis, involving a total of 108,136 PCa cases from 39 observational studies, examined the association of the use of any NSAID with the risk of PCa incidence or mortality. The major finding of the present meta-analysis provides support for the mechanistic hypothesis that aspirin use (including long-term use of more than four years) is inversely related to the risk of PCa incidence. The association was slightly stronger for advanced PCa than for total PCa (OR = 0.92 for total PCa, OR = 0.81 for advanced PCa). A cumulative meta-analysis showed that a statistically significant effect of aspirin use on PCa incidence was consistently observed after publication of the 13th trial in 2006. More importantly, aspirin use demonstrated a 14% decrease in PCa-specific mortality for total PCa compared to non-use. In general, the pooled effects for any NSAIDs, NA-NSAIDs and COX-2 inhibitors demonstrated no adverse or beneficial effects on PCa development or PCa-specific survival, but the results were not consistent; all the effect estimates varied by geographic region.

There is a long-standing debate about the relationship between NSAID use and cancer. Several reviewed studies discussed the potential chemoprevention effects of NSAID use against tumors at various sites, including breast \[[@B57]\], lung \[[@B58]\] and brain \[[@B59]\], and melanoma \[[@B60]\]. This meta-analysis, with a much larger number of participants than previous meta-analyses \[[@B38],[@B61]\], adds to the previous findings by showing that aspirin use demonstrates a protective effect against PCa. With a larger sample size, increased statistical power could be obtained. In addition, we evaluated whether the association varied by COX-2 inhibitor, long-term aspirin use and study quality, and we investigated whether NSAID use influenced mortality from the disease, issues that were not discussed in the primary meta-analysis. Moreover, the present studies included an approved quality evaluation system; thus, it was more reliable in minimizing potential bias.

There are several proposed mechanisms by which these effects could be explained. Primary laboratory studies have pointed to COX-2 overexpression in PCa tissue \[[@B3]\], and it is well established that increased expression of COX-2 is related to tumor growth \[[@B4]\] and poorer prognosis \[[@B5]\]. NSAIDs inhibit PCa cell growth by reducing the synthesis of prostaglandins by COX enzymes \[[@B62]\], including inducing apoptosis \[[@B63]\], inhibiting cellular proliferation and angiogenesis \[[@B64]\]. Animal and laboratory studies have confirmed the preventive effect of NSAIDs on PCa repeatedly and consistently. In a review of 12 studies, the authors reported that, in all the included studies, all types of NSAIDs exhibited inhibitory effects on PCa development and progression.

In our study, use of aspirin was significantly inversely related to the risks of developing advanced PCa but not non-advanced PCa, which is difficult to explain. It may possibly be explained by detection bias if aspirin users were more likely to be screened and, therefore, to be diagnosed at an earlier stage. However, this effect may be real. Laboratory studies have suggested that advanced stage PCa may represent heterogeneous etiologies \[[@B65]\] and the mechanism by which aspirin acts on the initiation of poorly-differentiated disease may be distinct from its influence on the development of advanced disease \[[@B20]\]. There was also evidence that NSAIDs evoke tumor regression in gastrointestinal tumors \[[@B66]\], and may have similar effects against cancers of other sites including the prostate. Our findings with regard to the effects of aspirin on disease severity require confirmation in larger studies using unbiased diagnostic approaches.

We postulated that the use of aspirin reduced overall PCa risk. This could have significant implications with respect to the dose, frequency and duration of aspirin use. Unfortunately, most studies lacked information on dosage, frequency and duration of exposure. Although some studies have provided this information, they varied in each trial, resulting in invalid statistical analysis in these groups. In a study by Veitonmaki *et al*. \[[@B37]\] in 2013, a dose--effect relationship was found, indicating a significant inverse association (OR = 0.83) only among participants who used aspirin at the dosage of 37 to 1,300 defined daily dose (DDD). The other benefit was shown among those who took more than one aspirin pill per day \[[@B23],[@B29],[@B34]\], a low dose (≤75 mg/daily) \[[@B27],[@B32]\], larger doses (≥325 mg/daily) \[[@B26]\] or more than six tablets/week \[[@B20]\]; nevertheless, other studies found no evidence of a dose--effect \[[@B7],[@B10],[@B17],[@B19],[@B33],[@B35]\] or frequency--effect \[[@B14],[@B16],[@B17]\] relationship. In terms of the duration of aspirin use, we used the available data from eight studies \[[@B15],[@B17]-[@B20],[@B26],[@B27],[@B32]\] with durations of more than four years. Our pooled results demonstrated a negative trend of PCa risk with more than four years of aspirin use.

Considering the high incidence of PCa and the widespread use of aspirin in the general population, therefore, successful prevention could have a major public health impact. However, physicians should be aware of which subgroups of the population are at high risk for PCa, and the optimal dosage of aspirin, as well as its side effects, should be addressed. It seems that the use of aspirin in clinical prevention still has a long way to go, but, at least, the evidence implies that it is beneficial against the risk of PCa.

Nevertheless, several limitations of this study must be acknowledged. First, heterogeneity was a potential problem when interpreting the results of our analysis. In our meta-analysis, significant heterogeneity was observed in many of the analyses we conducted. Despite stratifying the data into subgroups based on type of outcome, study design, geographic region, quality of study and duration of aspirin use, some heterogeneity was still detected. In fact, it is no surprise given the differences of each study in the definition of drug exposure, information collection methods (for example, questionnaires or medical records), race, age and lifestyle factors of participants, sample size, duration of study follow-up and so on.

Second, as shown in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}, the number and content of the adjusted confounders differed among studies, which could have caused some imprecision in the effect estimates. The established risk factors for PCa are African-American ethnicity and family history of PCa \[[@B65]\]. Most studies adjusted for age and race using multivariate statistical models. Few studies adjusted for family history of PCa. However, researchers do not always make the same decisions concerning confounding factors. We did our best to minimize these confounding biases by choosing the most multivariable adjusted-effect estimates to analyze.

In addition, several sources of bias could have affected our observed associations. First, observational studies have inherent limitations, notably bias and unmeasured confounding. On the other hand, screening and surveillance biases are potentially a major source of systemic error in the reviewed studies. NSAID use may be associated with the socioeconomic status of patients. Thus, NSAID users might maintain healthier lifestyle habits than non-users, which could influence their risk for PCa. Moreover, NSAID users may have easier and more frequent access to preventive healthcare services, such as screening for prostate-specific antigen (PSA), which theoretically could lower the incidence of PCa.

At this stage, randomized controlled trials (RCTs) would be required to evaluate further the relationship between NSAIDs and PCa risk. However, RCTs for this topic could be extremely difficult or even impossible. First, PCa is rare and mainly occurs in older men; second, too many people in the general population take NSAIDs, especially aspirin, for various important medical reasons. This will render randomization and adherence to the protocol impossible. If one wants to conduct such a trial in younger subjects who do not take NSAIDS, investigators will run into the trouble of having enough end-points (events) given their young age.

Conclusions
===========

Our current study, based on the available studies and updated data from a previous meta-analysis, supports the hypothesis that aspirin use (including long-term use) provides potential benefits in the reduction of PCa incidence and PCa-specific mortality. The inverse association was slightly stronger for advanced PCa than for total PCa, but the effect estimates varied by geographic region. Also unclear is the influence of dose and the frequency of aspirin use on PCa incidence and outcomes. Thus, caution needs to be exercised to ensure that the associated prevention benefits of aspirin outweigh the potential side effects (for example. gastrointestinal bleeding).
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